Takayasu's arteritis medical therapy

Takayasu's arteritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Takayasu's arteritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
Echocardiography and Ultrasound
CT Scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Takayasu's arteritis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Takayasu's arteritis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on Takayasu's arteritis medical therapy
on Takayasu's arteritis medical therapy
Takayasu's arteritis medical therapy in the news
Blogs onTakayasu's arteritis medical therapy
Directions to Hospitals Treating Takayasu's arteritis
Risk calculators and risk factors for Takayasu's arteritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]

Medical Therapy

Medical therapy of Takayasu arteritis depends on the disease activity and the complications that develop.

The two most important aspects of treatment:

• Controlling the inflammatory process
• Controlling hypertension

Corticosteroids

• Corticosteroids are the mainstay of therapy for active Takayasu arteritis

• Most people with Takayasu’s arteritis respond to steroids such as prednisone

• The usual starting dose is approximately 1 milligram per kilogram of body weight per day
• Long-term, low-dose corticosteroid therapy may be required
• Osteoporosis prevention when patients are started on corticosteroids should be considered

IL-6 receptor inhibitor

• Humanized monoclonal antibody tocilizumab suggested as a treatment for Takayasu arteritis through blockade of the soluble interleukin-6 (IL-6) receptor.